{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:13:14Z","timestamp":1777158794601,"version":"3.51.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic Hepatitis C Virus (HCV) infection is associated with systemic metabolic disturbances, including glucose intolerance, lipid dysregulation, and inflammation, accelerating liver fibrosis and increasing hepatocellular carcinoma risk. Biomarkers such as Glucagon-Like Peptide-1 (GLP-1), Fatty Acid-Binding Protein 1 (FABP-1), Monocyte Chemoattractant Protein-1 (MCP-1), Angiopoietin-Like Protein 6 (ANGPTL6), ibroblast Growth Factor 19 (FGF-19), and ghrelin offer insights into these mechanisms and may reflect the impact of antiviral treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the effects of two direct-acting antiviral (DAA) regimens\u2014Glecaprevir\/Pibrentasvir (G\/P) and Sofosbuvir\/Velpatasvir (S\/V)\u2014on metabolic and inflammatory biomarkers in 70 HCV-infected patients with comorbidities including obesity, type 2 diabetes, and hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum biomarker levels were assessed pre- and post-treatment using the Luminex FlexMAP 3D system. Patients were stratified by treatment type, fibrosis stage (F0\u2013F4), and baseline cholesterol. Liver stiffness was evaluated via FibroScan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both regimens induced significant biomarker changes. ANGPTL6, FGF-19, ghrelin, total cholesterol, HDL, and non-HDL increased, while FABP-1 and MCP-1 decreased, indicating reduced inflammation and lipid stress. Stronger effects were seen in patients with lower baseline cholesterol and with S\/V in advanced fibrosis. G\/P showed marked anti-inflammatory effects in early fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DAA therapy significantly alters metabolic and inflammatory biomarkers in HCV patients, with regimen- and fibrosis stage-specific effects. S\/V may provide broader metabolic benefits in advanced disease, while G\/P offers stronger anti-inflammatory responses earlier, supporting personalized treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1729835","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:33:17Z","timestamp":1771997597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of antiviral treatment in hepatitis C patients on metabolism and fibrosis process"],"prefix":"10.3389","volume":"13","author":[{"given":"Malwina","family":"J\u0119drysik","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Che\u0142stowska","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip M.","family":"Szyma\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University","place":["Warsaw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3748\/wjg.v28.i22.2429","article-title":"Metabolic aspects of hepatitis C virus","volume":"28","author":"El-Kassas","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3748\/wjg.v27.i13.1267","article-title":"Metabolic complications of hepatitis C virus infection","volume":"27","author":"Chaudhari","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/v8060152","article-title":"Adapting the stress response: viral subversion of the mTOR signaling pathway","volume":"8","author":"Le Sage","year":"2016","journal-title":"Viruses"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1016\/j.ijid.2013.01.027","article-title":"Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway","volume":"17","author":"Yu","year":"2013","journal-title":"Int J Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3748\/wjg.v20.i11.2825","article-title":"Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis","volume":"20","author":"Vespasiani-Gentilucci","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2024.1454980","article-title":"Signaling pathways that activate hepatic stellate cells during liver fibrosis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on \u03b2-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.154314","article-title":"Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression","volume":"8","author":"Trzaskalski","year":"2023","journal-title":"JCI Insight"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1440-1746.2007.05183.x","article-title":"Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance","volume":"23","author":"Itou","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fendo.2015.00134","article-title":"Diabetes and hepatitis C: a two-way association","volume":"6","author":"Hammerstad","year":"2015","journal-title":"Front Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.3390\/ijms20184569","article-title":"Liraglutide inhibits hepatitis c virus replication through an AMP activated protein kinase dependent mechanism","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"11549","DOI":"10.1073\/pnas.0912426107","article-title":"Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase","volume":"107","author":"Mankouri","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.arcmed.2012.11.007","article-title":"Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection","volume":"44","author":"Akbal","year":"2013","journal-title":"Arch Med Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3748\/wjg.v21.i38.10776","article-title":"Modulation of host lipid metabolism by hepatitis C virus: role of new therapies","volume":"21","author":"Campo","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"18229","DOI":"10.18632\/oncotarget.7571","article-title":"Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma","volume":"7","author":"Ku","year":"2016","journal-title":"Oncotarget"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.3748\/wjg.v17.i46.5097","article-title":"Serum leptin and ghrelin in chronic hepatitis C patients with steatosis","volume":"17","author":"Pavlidis","year":"2011","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ijms231911188","article-title":"Role of the ghrelin system in colitis and hepatitis as risk factors for inflammatory-related cancers","volume":"23","author":"Kasprzak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/liv.12235","article-title":"Independent factors associated with altered plasma active ghrelin levels in HCV-infected patients","volume":"33","author":"Kawaguchi","year":"2013","journal-title":"Liver Int"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.3748\/wjg.v10.i24.3639","article-title":"Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C","volume":"10","author":"Panasiuk","year":"2004","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1172\/JCI26498","article-title":"MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity","volume":"116","author":"Kanda","year":"2006","journal-title":"J Clin Invest"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0016-5085(03)01213-7","article-title":"A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease","volume":"125","author":"M\u00fchlbauer","year":"2003","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1210\/clinem\/dgaa103","article-title":"Serum angiopoietin-like protein 6, risk of type 2 diabetes, and response to hyperglycemia: a prospective cohort study","volume":"105","author":"Fan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"16393","DOI":"10.20452\/pamw.16393","article-title":"Associations of ANGPTL6, DOCK6, FABP1, and PCSK9 single-nucleotide variants with hypercholesterolemia in the polish population: a cross-sectional study","volume":"133","author":"\u015awiderska","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0116928","article-title":"Perturbations of fibroblast growth factors 19 and 21 in type 2 diabetes","volume":"10","author":"Roesch","year":"2015","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2022.111617","article-title":"Fibroblast growth factor 15\/19 expression, regulation, and function: an overview","volume":"548","author":"Guthrie","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fendo.2021.799382","article-title":"Virus elimination by direct-acting antiviral agents impacts glucose homeostasis in chronic hepatitis C patients","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/9781118819951.ch4","article-title":"Sofosbuvir (Sovaldi): the first-in-class HCV NS5B nucleotide polymerase inhibitor","volume":"4","author":"Schinazi","year":"2015","journal-title":"Innov Drug Synthesis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2147\/DDDT.S172512","article-title":"Glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy","volume":"13","author":"Cotter","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-021-01481-1","article-title":"Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Ke","year":"2021","journal-title":"Lipids Health Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.phrs.2022.106426","article-title":"Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: an experimental to clinical perspective","volume":"184","author":"Yadav","year":"2022","journal-title":"Pharmacol Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/CM9.0000000000003629","article-title":"MASLD development: from molecular pathogenesis toward therapeutic strategies","volume":"138","author":"Yang","year":"2025","journal-title":"Chin Med J"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/liv.16169","article-title":"MASLD, at-risk MASH and increased liver stiffness are associated with young adulthood obesity without residual risk after losing obesity","volume":"45","author":"van Kleef","year":"2025","journal-title":"Liver Int"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-025-01630-y","article-title":"Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis","volume":"19","author":"Zhou","year":"2025","journal-title":"BMC Chem"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/ni.3680","article-title":"Defining B cell immunodominance to viruses","volume":"18","author":"Angeletti","year":"2017","journal-title":"Nat Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.immuni.2020.12.001","article-title":"The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells","volume":"54","author":"Yousif","year":"2021","journal-title":"Immunity"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/ptr.7936","article-title":"Medicinal plant molecules against hepatitis C virus: current status and future prospect","volume":"37","author":"Mandal","year":"2023","journal-title":"Phytother Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0068992","article-title":"Antiviral activity of glycyrrhizin against hepatitis C virus in vitro","volume":"8","author":"Matsumoto","year":"2013","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","article-title":"Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase","volume":"138","author":"Ahmed-Belkacem","year":"2010","journal-title":"Gastroenterology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1128\/jvi.01473-15","article-title":"Polyphenols inhibit hepatitis C virus entry by a new mechanism of action","volume":"89","author":"Calland","year":"2015","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1111\/j.1365-2893.2011.01507.x","article-title":"Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity","volume":"19","author":"Bachmetov","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5114\/ceh.2024.141752","article-title":"Effectiveness of glecaprevir\/pibrentasvir in HIV\/HCV-coinfected patients treated with bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"10","author":"Berkan-Kawi\u0144ska","year":"2024","journal-title":"Clin Exp Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.14218\/JCTH.2020.00078","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hcv infection","volume":"9","author":"Liu","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.70074","article-title":"Glecaprevir\/pibrentasvir versus sofosbuvir\/velpatasvir for hepatitis C virus genotype 6: a systematic review and meta-analysis","volume":"35","author":"Le","year":"2025","journal-title":"Rev Med Virol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1729835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:33:18Z","timestamp":1771997598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1729835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":48,"alternative-id":["10.3389\/fmed.2026.1729835"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1729835","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1729835"}}